Literature DB >> 33489148

Unusual clinical presentation of cutaneous leishmaniasis in a patient with corticosteroid-induced immunosuppression.

Maryam Mahdavi1, Reihaneh Aryan1, Yalda Nahidi1, Mehrdad Teimoorian2, Vahid Mashayekhi1.   

Abstract

Clinicians should always consider rare, atypical, and opportunistic infections in patients undergoing long-term systemic corticosteroid therapy. Diagnosis needs further evaluations and special consideration.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cutaneous leishmaniasis; disseminated; immunosuppression; recurrence; systemic corticosteroids

Year:  2020        PMID： 33489148      PMCID： PMC7813036          DOI： 10.1002/ccr3.3482

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  15 in total

1.  Disseminated leishmaniasis caused by Leishmania tropica in HIV-positive patients in the Islamic Republic of Iran.

Authors:  S Jafari; M Hajiabdolbaghi; M Mohebali; H Hajjaran; H Hashemian
Journal:  East Mediterr Health J       Date:  2010-03       Impact factor: 1.628

Review 2.  Leishmaniasis in immunosuppressed individuals.

Authors:  J van Griensven; E Carrillo; R López-Vélez; L Lynen; J Moreno
Journal:  Clin Microbiol Infect       Date:  2014-02-20       Impact factor: 8.067

Review 3.  Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review.

Authors:  Ali Zandieh; Basira Zandieh; Ladan Dastgheib
Journal:  Int J Dermatol       Date:  2013-01       Impact factor: 2.736

Review 4.  Leishmaniasis.

Authors:  David Pace
Journal:  J Infect       Date:  2014-09-17       Impact factor: 6.072

5.  Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient.

Authors:  Marjan Mirzabeigi; Uzma Farooq; Sean Baraniak; Lorraine Dowdy; Gaetano Ciancio; Vladimir Vincek
Journal:  J Cutan Pathol       Date:  2006-10       Impact factor: 1.587

6.  Intralesional injection of 2% zinc sulfate solution in the treatment of acute old world cutaneous leishmaniasis: a randomized, double-blind, controlled clinical trial.

Authors:  Alireza Firooz; Alireza Khatami; Ali Khamesipour; Mansour Nassiri-Kashani; Fereydoun Behnia; Mohammadali Nilforoushzadeh; Hamidreza Pazoki-Toroudi; Yahya Dowlati
Journal:  J Drugs Dermatol       Date:  2005 Jan-Feb       Impact factor: 2.114

7.  Leishmaniasis in a heart transplant patient.

Authors:  A Golino; J M Duncan; B Zeluff; J DePriest; H A McAllister; B Radovancevic; O H Frazier
Journal:  J Heart Lung Transplant       Date:  1992 Jul-Aug       Impact factor: 10.247

8.  Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report.

Authors:  Felipe Francisco Tuon; Valdir Sabbaga Amato; Lucile Maria Floeter-Winter; Ricardo de Andrade Zampieri; Vicente Amato Neto; Francisco Oscar Siqueira França; Maria Aparecida Shikanai-Yasuda
Journal:  Int J Dermatol       Date:  2007-06       Impact factor: 2.736

9.  Recurrence of visceral and muco-cutaneous leishmaniasis in a patient under immunosuppressive therapy.

Authors:  Gilles Darcis; Gert Van der Auwera; Jean-Baptiste Giot; Marie-Pierre Hayette; Françoise Tassin; Jorge Arrese Estrada; Lieselotte Cnops; Michel Moutschen; Laurence de Leval; Philippe Leonard
Journal:  BMC Infect Dis       Date:  2017-07-07       Impact factor: 3.090

10.  Old world cutaneous leishmaniasis in Iran: clinical variants and treatments.

Authors:  Alireza Firooz; Hossein Mortazavi; Ali Khamesipour; Maryam Ghiasi; Robabeh Abedini; Kamran Balighi; Nafiseh Esmaili; Mansour Nassiri-Kashani; S Ebrahim Eskandari; Mehdi Mohebali; Akram Mir Amin Mohammadi; Yahya Dowlati
Journal:  J Dermatolog Treat       Date:  2020-01-08       Impact factor: 3.359
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.